Pakin Jarerndee/iStock via Getty Images CytoSorbents Corporation ( NASDAQ: CTSO ) Monday announced the regulatory approval of its CytoSorb device in Taiwan by the Taiwan Food and Drug Administration. The approved indications include the extracorporeal removal of cytokines (e.g.
cytokine storm, sepsis), bilirubin (e.g. liver disease), and myoglobin (e.
g. trauma) from a patient’s circulating blood. The removal of the antithrombotic drugs Brilinta (ticagrelor, AstraZeneca) and Xarelto (rivaroxaban, Janssen/Bayer) during cardiothoracic surgery is also approved, with the goal of reducing perioperative bleeding, CytoSorbents ( CTSO ) said in a statement.
CytoSorb will be distributed throughout Taiwan by Hemoscien Corporation. In addition to Taiwan, CytoSorb is approved in the European Union and distributed in 75 countries worldwide. Source: Press Release More on Cytosorbents Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Cytosorbents Historical earnings data for Cytosorbents Financial information for Cytosorbents.
